What question did this study set out to answer?

This research aims to explore the activity of copper(II) benzyloxychalcone analogues in inhibiting SARS-CoV-2 replication.

May 7, 2026Open Access

Copper(II) benzyloxychalcone analogues as new potential metallodrugs against SARS-CoV-2 replication

Key Points

This research aims to explore the activity of copper(II) benzyloxychalcone analogues in inhibiting SARS-CoV-2 replication.
Evaluated the effects of Cu(II) benzyloxychalcone analogues on SARS-CoV-2 entry and RNA replication.
Investigated the mechanism of action involving disruption of the viral envelope and dsRNA intercalation.
Demonstrated that Cu(II) benzyloxychalcone analogues impair SARS-CoV-2 entry.
Interfered with RNA replication by intercalating into dsRNA, suggesting a dual mechanism of action.

Abstract

phen acts by impairing SARS-CoV-2 entry by disrupting the viral envelope as well as interrupting RNA replication through specifically intercalating into the dsRNA. The obtained results give us mechanistic insights into the activity of this promising Cu(II) metallodrug candidate in SARS-CoV-2 infection.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Igor Andrade Santos

Victória Riquena Grosche

Laiane dos Santos Oliveira

Journals

Journal of General Virology

Actions

Institutions

University of Leeds

Universidade Estadual de Campinas (UNICAMP)

University of Tartu

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Copper(II) benzyloxychalcone analogues as new potential metallodrugs against SARS-CoV-2 replication

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study